ClubVision since Mar 2011
Co-Founder & Executive Chairman
Excella Bioscience Consulting / Excella Capital Partners LLP since Jan 2010
Founder and Principal
Sera Prognostics Apr 2011 - Mar 2012
President and Chief Operating Officer
Perlegen Sciences Jan 2009 - Nov 2009
Senior Vice President, Sales & Marketing
GenVault Corporation Jan 2008 - Jan 2009
VP, Global Sales and Marketing
Education:
Yale University 1981 - 1986
BA
Skills:
Oncology Commercialization Medical Devices Lifesciences Biotechnology Genetics Market Development Molecular Diagnostics Start Ups Genomics Managed Care Cancer Pharmaceutical Industry Immunology Biomarkers Molecular Biology Strategy Clinical Trials Clinical Development Sales Operations Personalized Medicine Biopharmaceuticals Biochemistry Entrepreneurship Infectious Diseases Strategic Partnerships Clinical Research Assay Development Hardware Diagnostics Proteomics Sequencing Drug Discovery Technology Transfer Biomarker Discovery Drug Development Product Launch Dna Sequencing Fda Venture Capital Protein Chemistry Executive Management Leadership Dna Informatics Laboratory Medical Diagnostics Cardiology Dermatology Healthcare Bioinformatics
Interests:
Mobile Response Clinical Trials Channel Screening Molecular Diagnostics Sales Prostate Biomarker Breakthrough Disruptive Biotechnology Interim Turnaround Manager Strategic Alliance Sequencing Gene Testing Management Funding Personalized Medicine Executive Signature Lung Officer Technology Personal Development Genotyping Consultant Ovarian Familial Genetic Susceptibility Financing Pathology Entrepreneur Location Based Services Oncology Esoteric Testing Specialty Serial High Performance Venture Capital Pharmacogenomics Molecular Seed Capital Laboratory Predisposition Angel Partner Coach Director Music Translational Research Mobile Advertising Molecular Biology Risk Assessment Marketing Genetic Testing Ventures For Good Breast Cancer Genetics Catalyst Sales Leader Prognostic Tumor Marker Pharmacogenetics International Distributor Genomics Gene Expression Profiling Accredited Investor Diagnostics Predictive Testing Medical Devices Charitable Giving Health Care Information Technology Colon Startup Hereditary Cancer Commercialization
Christopher Weist (1999-2003), Susan Arthur (1978-1982), Norene McAdams (1974-1978), Rich Krahe (1978-1982), Mark Ostrowski (1985-1989), Margaret Zuno (1957-1961)
"Moving to the encryption scheme of AES 256-bit GCMshould be a sufficient move to support the expected level of encryption for streaming conference data," Mark Ostrowski, the head of engineeringat Check Point Security, said. "Additionally, adding Data Routing Control a user can also omit Zoom da